ClinicalTrials.gg
CompletedNCT03539913SABINAUpdated Jan 22, 2019

Efficacy and Safety of Probiotics in the Treatment of Acute Gastroenteritis in Children

A Phase 4 interventional study of Probiotic : Saccharomyces boulardii and Probiotic : Bacillus clausii in Acute Gastroenteritis, sponsored by Biocodex. Completed at 8 sites in Argentina. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2019-01-22.

Sponsored by Biocodex · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jun 2017, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
317
Allocation
Randomized
Ages
6 Months to 5 Years
Sex
All
01

Study summary

  • Primary Objective:

    o To assess the efficacy of the probiotics in reducing the duration of diarrhea in children suffering from acute gastroenteritis.

  • Secondary Objectives:

    • To assess the efficacy of the probiotics in improving the frequency and consistency of stools.
    • To assess the efficacy of the probiotics in avoiding recurrence of diarrhea.
    • To assess the efficacy of the probiotics on the disease severity.
    • To assess the safety and tolerability of the studied probiotics.
02

Conditions studied

  • Acute Gastroenteritis

Browse trials for

03

In context

Gastroenteritis

237 studies on the registry are indexed under Gastroenteritis; 16 are open to participants now.

This study's enrollment of 317 is above the median of 136 across 164 interventional studies indexed under Gastroenteritis.

Browse Gastroenteritis studies →

Lead sponsor

Biocodex is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children of both gender aged between 6 months and 5 years
  • Presenting with acute diarrhea (3 or more loose or liquid stools in a 24-hour period) since at least the last 24h but less than 5 days
  • Signed of the legal representatives obtained before any study procedure
  • Parents able to fulfill in the stool diary according to the physician's opinion.

Exclusion criteria

Exclusion Criteria:

  • Unable to take medication and fluids by mouth
  • More than 50% breastfeeding
  • Severe malnutrition, defined by a ratio weight/height at/or below -3SD
  • Severe dehydration, defined by a need of IV rehydration
  • Chronic underlying disease, including but not limited to severe gastrointestinal disorder, condition or systemic infection
  • Use of prohibited treatments
  • to the studied probiotics
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
317 participants (actual)

Study arms

  • Active comparator
    Saccharomyces boulardii

    Floratil, 250 mg sachets, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.

    Biological: Probiotic : Saccharomyces boulardii

  • Active comparator
    Bacillus clausii

    Enterogermina, 5 ml vials, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.

    Biological: Probiotic : Bacillus clausii

Interventions

06

What researchers measure

Primary outcomes

  1. Time frame in hours up to the time of the last liquid or loose stool as recorded in the stool diary

    Time frame in hours up to the time of the last liquid or loose stoll (defined as type 6 or 7 on Bristol Stool Scale) followed by the first 24-hour period with stool consistency improvement (no liquid or loose stool), i.e. cessation of diarrhea as recorded by the parents in the stool diary.

    Time frame: 5 days

07

Study locations

8 sites
  • Instituto Medico
    Río Cuarto, Provincia De Cordoba, Argentina
  • Instituto Medico
    San Juan, Provincia De San Juan, Argentina
  • Instituto Medico
    San Miguel De Tucumán, Tucuman, Argentina
  • Consultario Privado 3
    Caba, Argentina
  • Consultorio Privado 1
    Caba, Argentina
  • Consultorio Privado 2
    Caba, Argentina
  • Consultorio Privado 4
    Caba, Argentina
  • Grupo Pediatrico
    Caba, Argentina
08

References and documents

Publications

  • Altcheh J, Carosella MV, Ceballos A, D'Andrea U, Jofre SM, Marotta C, Mugeri D, Sabbaj L, Soto A, Josse C, Montestruc F, McFarland LV. Randomized, direct comparison study of Saccharomyces boulardii CNCM I-745 versus multi-strained Bacillus clausii probiotics for the treatment of pediatric acute gastroenteritis. Medicine (Baltimore). 2022 Sep 9;101(36):e30500. doi: 10.1097/MD.0000000000030500. PubMed 36086703 ↗
  • Collinson S, Deans A, Padua-Zamora A, Gregorio GV, Li C, Dans LF, Allen SJ. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2020 Dec 8;12(12):CD003048. doi: 10.1002/14651858.CD003048.pub4. PubMed 33295643 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Jun 2018, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2018
First posted
May 30, 2018
StartActual
Jun 19, 2017
Primary completionActual
Jun 9, 2018
CompletionActual
Jun 9, 2018
Last update
Jan 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03539913
Lead sponsor
Biocodex
Responsible party
Sponsor
First posted
May 30, 2018
Start date
Jun 19, 2017
Primary completion
Jun 9, 2018
Completion
Jun 9, 2018
Last update
Jan 22, 2019

Study contacts

Carine FRANCOIS
study director · Biocodex

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saccharomyces cerevisiae · Probiotic

Start the discussion